Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19
Lawler, P. R.; Goligher, E. C.; Berger, J. S.; Neal, M. D.; McVerry, B. J.; Nicolau, J. C.; Gong, M. N.; Carrier, M.; Rosenson, R. S.; Reynolds, H. R.; Turgeon, A. F.; Escobedo, J.; Huang, D. T.; Bradbury, C. A.; Houston, B. L.; Kornblith, L. Z.; Kumar, A.; Kahn, S. R.; Cushman, M.; McQuilten, Z.; Slutsky, A. S.; Kim, K. S.; Gordon, A. C.; Kirwan, B.-A.; Brooks, M. M.; Higgins, A. M.; Lewis, R. J.; Lorenzi, E.; Berry, S. M.; Berry, L. R.; Angus, D. C.; McArthur, C. J.; Webb, S. A.; Farkouh, M. E.; Hochman, J. S.; Zarychanski, R.
Show abstract
BackgroundThrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients hospitalized for Covid-19. MethodsIn an open-label adaptive multiplatform randomized controlled trial, non-critically ill patients hospitalized for Covid-19, defined by the absence of critical care-level organ support at enrollment, were randomized to a pragmatic strategy of therapeutic-dose anticoagulation with heparin or usual care pharmacological thromboprophylaxis. The primary outcome combined survival to hospital discharge and days free of organ support through 21 days, which was evaluated with Bayesian statistical models according to baseline D-dimer. ResultsThe trial was stopped when prespecified criteria for superiority were met for therapeutic-dose anticoagulation in groups defined by high ([≥]2-fold elevated) and low (<2-fold elevated) D-dimer. Among 2219 participants in the final analysis, the probability that therapeutic anticoagulation increased organ support-free days compared to thromboprophylaxis was 99.0% (adjusted odds ratio 1.29, 95% credible interval 1.04 to 1.61). The adjusted absolute increase in survival to hospital discharge without organ support with therapeutic-dose anticoagulation was 4.6% (95% credible interval 0.7 to 8.1). In the primary adaptive stopping groups, the final probabilities of superiority for therapeutic anticoagulation were 97.3% in the high D-dimer group and 92.9% in the low D-dimer group. Major bleeding occurred in 1.9% and 0.9% of participants randomized to therapeutic anticoagulation and thromboprophylaxis, respectively. ConclusionsIn non-critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increases the probability of survival to hospital discharge with reduced use of organ support. Trial registration numbers: NCT02735707, NCT04505774, NCT04359277, NCT04372589
Matching journals
The top 6 journals account for 50% of the predicted probability mass.